An At-Risk Population Screening Program for Mucopolysaccharidoses by Measuring Urinary Glycosaminoglycans in Taiwan

Background: The mucopolysaccharidoses (MPSs) are a group of rare lysosomal storage disorders characterized by the accumulation of glycosaminoglycans (GAGs) and which eventually cause progressive damage to various tissues and organs. We developed a feasible MPS screening algorithm and established a cross-specialty collaboration platform between medical geneticists and other medical specialists based on at-risk criteria to allow for an earlier confirmative diagnosis of MPS. Methods: Children (<19 years of age) with clinical signs and symptoms compatible with MPS were prospectively enrolled from pediatric clinics between July 2013 and June 2018. Urine samples were collected for a non-specific total GAG analysis using the dimethylmethylene blue (DMB) spectrophotometric method, and the quantitation of three urinary GAGs (dermatan sulfate (DS), heparan sulfate (HS), and keratan sulfate (KS)) was performed by liquid chromatography/tandem mass spectrometry (LC-MS/MS). The subjects with elevated urinary GAG levels were recalled for leukocyte enzyme activity assay and genetic testing for confirmation. Results: Among 153 subjects enrolled in this study, 13 had a confirmative diagnosis of MPS (age range, 0.6 to 10.9 years—three with MPS I, four with MPS II, five with MPS IIIB, and one with MPS IVA). The major signs and symptoms with regards to different systems recorded by pediatricians at the time of the decision to test for MPS were the musculoskeletal system (55%), followed by the neurological system (45%) and coarse facial features (39%). For these 13 patients, the median age at the diagnosis of MPS was 2.9 years. The false negative rate of urinary DMB ratio using the dye-based method for these 13 patients was 31%, including one MPS I, two MPS IIIB, and one MPS IVA. However, there were no false negative results with urinary DS, HS and KS using the MS/MS-based method. Conclusions: We established an at-risk population screening program for MPS by measuring urinary GAG fractionation biomarkers using the LC-MS/MS method. The program included medical geneticists and other medical specialists to increase awareness and enable an early diagnosis by detecting MPS at the initial onset of clinical symptoms.

[1]  Hsiang-Yu Lin,et al.  Normalization of glycosaminoglycan-derived disaccharides detected by tandem mass spectrometry assay for the diagnosis of mucopolysaccharidosis , 2019, Scientific Reports.

[2]  W. Hwu,et al.  Functional independence of Taiwanese patients with mucopolysaccharidoses , 2019, Molecular genetics & genomic medicine.

[3]  S. Tomatsu,et al.  Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments , 2019, Drugs.

[4]  W. Hwu,et al.  Long-term effects of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis IVA. , 2019, Pediatrics and neonatology.

[5]  W. Hwu,et al.  Ophthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses , 2019, Molecular genetics & genomic medicine.

[6]  Yasuyuki Suzuki,et al.  Biomarkers in patients with mucopolysaccharidosis type II and IV , 2019, Molecular genetics and metabolism reports.

[7]  M. Gelb,et al.  Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI , 2019, The Journal of pediatrics.

[8]  Hsiang-Yu Lin,et al.  Long-term outcomes of enzyme replacement therapy for Taiwanese patients with Mucopolysaccharidosis I. , 2019, Pediatrics and neonatology.

[9]  Hsiang-Yu Lin,et al.  Awareness of attenuated mucopolysaccharidoses in a pediatric orthopedic clinic. , 2019, Pediatrics and neonatology.

[10]  John J. Mitchell,et al.  Understanding the Early Presentation of Mucopolysaccharidoses Disorders: Results of a Systematic Literature Review and Physician Survey , 2018 .

[11]  Hsiang-Yu Lin,et al.  The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses , 2018, Molecular genetics & genomic medicine.

[12]  S. Khan,et al.  Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. , 2018, Molecular genetics and metabolism.

[13]  W. Hwu,et al.  Mucopolysaccharidosis III in Taiwan: Natural history, clinical and molecular characteristics of 28 patients diagnosed during a 21‐year period , 2018, American journal of medical genetics. Part A.

[14]  Y. Chien,et al.  Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS) , 2018, Orphanet Journal of Rare Diseases.

[15]  Hsiang-Yu Lin,et al.  Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan , 2018, Orphanet Journal of Rare Diseases.

[16]  C. Whitley,et al.  A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. , 2018, Molecular genetics and metabolism.

[17]  F. Wijburg,et al.  Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications , 2018, Orphanet Journal of Rare Diseases.

[18]  M. Fuller,et al.  Glycosaminoglycan fragments as a measure of disease burden in the mucopolysaccharidosis type I mouse. , 2017, Molecular genetics and metabolism.

[19]  T. Okuyama,et al.  Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up , 2017, Molecular genetics and metabolism reports.

[20]  M. Couce,et al.  A selective screening program for the early detection of mucopolysaccharidosis: Results of the FIND project – a 2-year follow-up study , 2017, Medicine.

[21]  Hsiang-Yu Lin,et al.  Awareness of Mucopolysaccharidosis in an Otorhinolaryngologic Clinic. , 2017, Pediatrics and neonatology.

[22]  John J. Mitchell,et al.  UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses. , 2016, Analytica chimica acta.

[23]  John J. Mitchell,et al.  Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. , 2016, Molecular genetics and metabolism.

[24]  A. Broomfield,et al.  The diagnostic journey of patients with mucopolysaccharidosis I: A real-world survey of patient and physician experiences , 2016, Molecular genetics and metabolism reports.

[25]  Hsiang-Yu Lin,et al.  Early Diagnosis for Mucopolysaccharidosis I - A 6-month-old Female Infant Presenting with Gibbus, Hirsutism and Mongolian Spots in a Well Baby Clinic , 2016 .

[26]  Y. Chien,et al.  Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series , 2016, Molecular genetics and metabolism reports.

[27]  D. Bertola,et al.  Short Communication Impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings. , 2016, Genetics and molecular research : GMR.

[28]  R. Giugliani,et al.  Emerging drugs for the treatment of mucopolysaccharidoses , 2016, Expert opinion on emerging drugs.

[29]  C. Phornphutkul,et al.  Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships , 2015, Orphanet Journal of Rare Diseases.

[30]  Hsiang-Yu Lin,et al.  Mucopolysaccharidosis I (Scheie syndrome): A rare cause of severe aortic stenosis in a 31-year-old man. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[31]  A. T. van der Ploeg,et al.  Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  T. Shimada,et al.  Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB. , 2015, JIMD reports.

[33]  Hsuan-Liang Liu,et al.  A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses , 2014, Orphanet Journal of Rare Diseases.

[34]  Hsiang-Yu Lin,et al.  Cardiovascular abnormalities in Taiwanese patients with mucopolysaccharidosis. , 2014, Molecular genetics and metabolism.

[35]  Hsiang-Yu Lin,et al.  Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses. , 2014, Molecular genetics and metabolism.

[36]  Shio‐Jean Lin,et al.  Characterization of pulmonary function impairments in patients with mucopolysaccharidoses—changes with age and treatment , 2014, Pediatric pulmonology.

[37]  W. Hwu,et al.  Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA , 2014, Orphanet Journal of Rare Diseases.

[38]  Hsuan-Liang Liu,et al.  A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan , 2013, Orphanet Journal of Rare Diseases.

[39]  Hsiang-Yu Lin,et al.  Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses , 2013, Orphanet Journal of Rare Diseases.

[40]  J. Muenzer.  Overview of the mucopolysaccharidoses. , 2011, Rheumatology.

[41]  J. Tolar,et al.  Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. , 2011, Clinical chemistry.

[42]  D. Millington,et al.  Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. , 2011, Molecular genetics and metabolism.

[43]  Chih-ping Chen,et al.  Polysomnographic characteristics in patients with mucopolysaccharidoses , 2010, Pediatric pulmonology.

[44]  B. Burton,et al.  Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome Survey , 2010, Genetics in Medicine.

[45]  Chih-ping Chen,et al.  Enzyme replacement therapy for mucopolysaccharidosis VI—experience in Taiwan , 2010, Journal of Inherited Metabolic Disease.

[46]  P. Arn,et al.  Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. , 2009, The Journal of pediatrics.

[47]  W. Hwu,et al.  Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004 , 2009, American journal of medical genetics. Part A.

[48]  P. Kaplan,et al.  Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. , 2008, Molecular genetics and metabolism.

[49]  S. Tomatsu,et al.  Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. , 2007, Analytical Biochemistry.

[50]  C. Eng,et al.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) , 2006, Genetics in Medicine.

[51]  J. E. Wraith,et al.  Mucopolysaccharidosis I under enzyme replacement therapy with laronidase—A mortality case with autopsy report , 2005, Journal of Inherited Metabolic Disease.

[52]  T. Taketani,et al.  Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses , 2005, Journal of Inherited Metabolic Disease.

[53]  M. Yuen,et al.  Diagnosis of classical Morquio's disease:N-acetylgalactosamine 6-sulphate sulphatase activity in cultured fibroblasts, leukocytes, amniotic cells and chorionic villi , 1985, Journal of Inherited Metabolic Disease.

[54]  P. Olczyk,et al.  Alterations of glycosaminoglycan metabolism in the development of diabetic complications in relation to metabolic control , 2005, Clinical chemistry and laboratory medicine.

[55]  J. Muenzer.  The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. , 2004, The Journal of pediatrics.

[56]  Joseph Muenzer,et al.  Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). , 2004, The Journal of pediatrics.

[57]  O. V. van Diggelen,et al.  A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease) , 2001, Journal of Inherited Metabolic Disease.

[58]  Lin Shuan-Pei,et al.  MPS screening methods, the berry spot and acid turbidity tests, cause a high incidence of false‐negative results in sanfilippo and morquio syndromes , 2002, Journal of clinical laboratory analysis.

[59]  S. P. Lin,et al.  Diagnostic screening for mucopolysaccharidoses by the dimethylmethylene blue method and two dimensional electrophoresis. , 2001, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.

[60]  S. Musumeci,et al.  Clinical and neuroradiological follow-up in mucopolysaccharidosis type III (Sanfilippo syndrome). , 1999, Neuropediatrics.

[61]  R. Wevers,et al.  Mucopolysaccharidoses Screening: Dimethylmethylene Blue versus Alcian Blue , 1994, Annals of clinical biochemistry.

[62]  I. Maire,et al.  Pitfalls of screening for mucopolysaccharidoses by the dimethylmethylene blue test. , 1993, Clinical chemistry.

[63]  P. McCourt,et al.  Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients. , 1991, American journal of human genetics.

[64]  R. Wevers,et al.  Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. , 1989, Clinical chemistry.

[65]  J. Hopwood,et al.  High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. , 1982, Analytical biochemistry.

[66]  J. Hopwood,et al.  A fluorometric assay using 4-methylumbelliferyl α-l-iduronide for the estimation of α-l-iduronidase activity and the detection of Hurler and Scheie syndromes , 1979 .

[67]  J. Hopwood,et al.  A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes. , 1979, Clinica chimica acta; international journal of clinical chemistry.

[68]  C. Epstein,et al.  Lack of relationship between blood and urine levels of glycosaminoglycans and lysomal enzymes. , 1975, Biochemical medicine.

[69]  R. Giugliani,et al.  The mucopolysaccharidoses. , 1976, Journal of medical genetics.